Humana Inc.
HUM Healthcare Healthcare Plans
Humana Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.7 billion, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 26.2%, EPS grew 27.9%, free cash flow grew 58.5% and total debt rose 13.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.
Follow HUM
Humana Inc. (HUM) Beneish M-score
Humana Inc.'s Beneish M-score for fiscal 2025 is −2.29; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −2.29 | 0.01 |
| FY2024 | −2.29 | 0.14 |
| FY2023 | −2.43 | 0.43 |
| FY2022 | −2.86 | (1.25) |
| FY2021 | −1.62 | 1.15 |
| FY2020 | −2.77 | 0.02 |
| FY2019 | −2.78 | (0.29) |
| FY2018 | −2.49 | 0.67 |
| FY2017 | −3.16 | (0.59) |
| FY2016 | −2.58 | (0.38) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 1.10 | — | 1.01 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 0.94 | — | 0.38 | |
| Sales growth index | 1.10 | — | 0.98 | |
| Depreciation index | 1.03 | — | 0.12 | |
| SG&A index SG&A not reported — index set to 1 | 1.00 | — | Set to 1 | −0.17 |
| Total accruals to total assets | 0.01 | — | 0.03 | |
| Leverage index | 0.97 | — | −0.32 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −2.29 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| CNC Centene Corporation compare | −3.1× |
| CVS CVS Health Corporation compare | −2.6× |
| CI Cigna Group compare | −2.5× |
| UNH UnitedHealth Group Incorporated compare | −2.4× |
| HUM Humana Inc. | −2.3× |
| ELV Elevance Health, Inc. compare | −2.3× |
| OSCR Oscar Health, Inc. compare | −2.2× |
| MOH Molina Healthcare, Inc compare | −2.0× |
| CLOV Clover Health Investments, Corp. compare | −1.7× |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI
More on HUM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement